Audio-Visual Gamma Stimulation for Circuit-Wide Amyloid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are palliative and lack effectiveness in inhibiting pathological progression, with existing therapies being toxic or ineffective, and there is a need for systems and methods that address circuit-wide disease affecting multiple brain centers responsible for learning and memory.
Innovation Solution
Non-invasive delivery of combined auditory and visual stimuli at frequencies of 20 to 60 Hz, specifically 35 to 45 Hz, to induce synchronized gamma oscillations in the brain, promoting microglial responses and reducing amyloid load across brain regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Aβ immunotherapy or secretase inhibition is used to reduce amyloid load, then amyloid plaque formation is targeted, but the treatments are toxic and ineffective at reducing AD pathology in clinical trials
Solution Approach 1:
The patent replaces pharmacological/chemical intervention systems (immunotherapy, secretase inhibitors) with a physical stimulation system (audio-visual stimuli) to achieve the same therapeutic goal of reducing amyloid load, thereby eliminating toxicity while maintaining effectiveness
Solution Approach 2:
The patent changes the approach from chemical parameter modification (drugs) to physical parameter modification (stimulus frequency 20-60 Hz, particularly 40 Hz gamma oscillations) to reduce amyloid load without the harmful side effects of pharmaceutical interventions
2Quantity of substance
If amyloid beta vaccines or gamma-secretase inhibitors are administered, then Aβ production or clearance is targeted, but cognitive deficits worsen and clinical trials fail
Solution Approach 1:
The patent substitutes chemical inhibition approaches (vaccines, secretase inhibitors) with physical brain stimulation to modulate Aβ metabolism, preserving cognitive function while achieving amyloid reduction through gamma oscillation-induced physiological changes
Solution Approach 2:
The patent employs periodic audio-visual stimuli at specific frequencies (20-60 Hz, particularly 40 Hz) to induce gamma oscillations that periodically activate neural circuits involved in amyloid clearance, avoiding the continuous harmful suppression caused by pharmacological inhibitors
3Reliability
If acetylcholinesterase inhibitors or NMDA-receptor antagonists are used, then cognitive symptoms are mildly improved, but the benefits are limited and side effects occur
Solution Approach 1:
The patent replaces enzymatic inhibition drugs (acetylcholinesterase inhibitors, NMDA antagonists) with physical brain stimulation to enhance cognitive function through gamma oscillation induction, achieving similar or superior benefits without the side effects of chronic medication
Solution Approach 2:
The patent enables the brain's own physiological mechanisms (gamma oscillations, microglial activation, amyloid clearance pathways) to self-regulate and improve cognitive function, rather than relying on external pharmacological agents that cause side effects
4Speed
If single-modality sensory stimulation (visual or auditory alone) is applied, then gamma oscillations are induced in specific regions, but circuit-wide disease affecting multiple brain centers is not adequately addressed
Solution Approach 1:
The patent merges visual and auditory stimulation modalities into a unified audio-visual stimulation system that simultaneously activates multiple brain circuits (visual cortex, auditory cortex, hippocampus, prefrontal cortex), achieving comprehensive circuit-wide disease modification that single modalities cannot accomplish
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined auditory and visual stimuli induce microglial clustering and reduce amyloid plaques throughout the neocortex, showing positive physiological and behavioral changes within weeks, ameliorating AD pathology in a large brain circuit network.
Implementation Method 1
Non-invasive delivery of combined auditory and visual stimuli at frequencies of 20 to 60 Hz, specifically 35 to 45 Hz, to induce synchronized gamma oscillations in the brain
Implementation Method 2
controlling at least one electroacoustic transducer to transduce an electrical audio signal into a corresponding auditory stimulus at a frequency of about 35 Hz to about 45 Hz
Implementation Method 3
controlling at least one visual stimulator to emit a visual stimulus at a frequency of about 35 Hz to about 45 Hz
Data Source
Figure 1A
Figure 1A
Figure 1B
AI summary
Devices, systems, and methods for a treating dementia or Alzheimer's disease in a subject in need thereof. In one example, combined auditory and visual stimuli having a frequency of about 20 Hz to about 60 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to induce synchronized gamma oscillations in at least one brain region of the subject. In particular, pursuant to various treatment and exposure protocols, combined auditory and visual stimulation (as opposed to auditory or visual stimulation alone) promotes a microglia response in the medial prefrontal cortex (mPFC). More generally, combined auditory and visual stimulation induces an extended microglia clustering response in the auditory cortex, the visual cortex, and the mPFC.